[
  {
    "ts": "2026-01-06T10:30:00+00:00",
    "headline": "Big Pharma Has More Going for It Than Obesity Drugs",
    "summary": "Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.",
    "url": "https://www.wsj.com/health/pharma/big-pharma-has-more-going-for-it-than-obesity-drugs-35ffd102?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "718b31ea-161c-37e0-b9a9-30d517b0adda",
      "content": {
        "id": "718b31ea-161c-37e0-b9a9-30d517b0adda",
        "contentType": "STORY",
        "title": "Big Pharma Has More Going for It Than Obesity Drugs",
        "description": "",
        "summary": "Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.",
        "pubDate": "2026-01-06T10:30:00Z",
        "displayTime": "2026-01-06T10:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/718b31ea-161c-37e0-b9a9-30d517b0adda/big-pharma-has-more-going-for.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/e4b5dcc738daaf9952e09fd2749449f5",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7RMo0RAoQIXBecVowGWgxA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/e4b5dcc738daaf9952e09fd2749449f5.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0b65xm2vuQmoOxj8Df4WNw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/e4b5dcc738daaf9952e09fd2749449f5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/big-pharma-has-more-going-for-it-than-obesity-drugs-35ffd102?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T09:40:00+00:00",
    "headline": "The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson",
    "summary": "Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026.",
    "url": "https://finance.yahoo.com/news/zacks-analyst-blog-eli-lilly-094000185.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "5342e76f-40d4-391a-a28e-da80e64d0195",
      "content": {
        "id": "5342e76f-40d4-391a-a28e-da80e64d0195",
        "contentType": "STORY",
        "title": "The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson",
        "description": "",
        "summary": "Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026.",
        "pubDate": "2026-01-06T09:40:00Z",
        "displayTime": "2026-01-06T09:40:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-eli-lilly-094000185.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-eli-lilly-094000185.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ISRG"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MDT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T09:34:00+00:00",
    "headline": "Zacks Investment Ideas feature highlights Pagaya, Eli Lilly and Weatherford",
    "summary": "Pagaya, Eli Lilly and Weatherford have been highlighted in this Investment Ideas article.",
    "url": "https://finance.yahoo.com/news/zacks-investment-ideas-feature-highlights-093400054.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "234c33cd-5548-3d7d-8eaa-89d674ed3a2e",
      "content": {
        "id": "234c33cd-5548-3d7d-8eaa-89d674ed3a2e",
        "contentType": "STORY",
        "title": "Zacks Investment Ideas feature highlights Pagaya, Eli Lilly and Weatherford",
        "description": "",
        "summary": "Pagaya, Eli Lilly and Weatherford have been highlighted in this Investment Ideas article.",
        "pubDate": "2026-01-06T09:34:00Z",
        "displayTime": "2026-01-06T09:34:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-investment-ideas-feature-highlights-093400054.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-investment-ideas-feature-highlights-093400054.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "WFRD"
            },
            {
              "symbol": "PGY"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "PLTR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T04:33:06+00:00",
    "headline": "2 Cash-Producing Stocks to Keep an Eye On and 1 We Ignore",
    "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
    "url": "https://finance.yahoo.com/news/2-cash-producing-stocks-keep-043306905.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "1f4ddb06-e0fb-355c-a3a2-773863b3387e",
      "content": {
        "id": "1f4ddb06-e0fb-355c-a3a2-773863b3387e",
        "contentType": "STORY",
        "title": "2 Cash-Producing Stocks to Keep an Eye On and 1 We Ignore",
        "description": "",
        "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
        "pubDate": "2026-01-06T04:33:06Z",
        "displayTime": "2026-01-06T04:33:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/727a6bbfc0df03ca73137e069e75f3f6",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "UBER Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wygrlfSkoupi0hpmhe.O_g--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/727a6bbfc0df03ca73137e069e75f3f6.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R9LiUKiId062gWopN8aXGQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/727a6bbfc0df03ca73137e069e75f3f6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-cash-producing-stocks-keep-043306905.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-cash-producing-stocks-keep-043306905.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MSCI"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "UBER"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T13:00:00+00:00",
    "headline": "Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment",
    "summary": "BOSTON, January 06, 2026--Nimbus Therapeutics, LLC (\"Nimbus Therapeutics\" or \"Nimbus\"), a drug discovery company developing breakthrough medicines through its AI-enhanced computational drug discovery engine, today announced it has entered into a multi-year research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company (\"Lilly\") to develop a novel oral treatment for obesity and other metabolic diseases.",
    "url": "https://finance.yahoo.com/news/nimbus-therapeutics-announces-research-collaboration-130000326.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "71c481d9-d7d4-381f-9f09-4f921d8923cf",
      "content": {
        "id": "71c481d9-d7d4-381f-9f09-4f921d8923cf",
        "contentType": "STORY",
        "title": "Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment",
        "description": "",
        "summary": "BOSTON, January 06, 2026--Nimbus Therapeutics, LLC (\"Nimbus Therapeutics\" or \"Nimbus\"), a drug discovery company developing breakthrough medicines through its AI-enhanced computational drug discovery engine, today announced it has entered into a multi-year research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company (\"Lilly\") to develop a novel oral treatment for obesity and other metabolic diseases.",
        "pubDate": "2026-01-06T13:00:00Z",
        "displayTime": "2026-01-06T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/902cc921431246d14ccd3804173e2b35",
          "originalWidth": 480,
          "originalHeight": 240,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TJj1pEWshrwngf8bvnHklQ--~B/aD0yNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/902cc921431246d14ccd3804173e2b35.cf.webp",
              "width": 480,
              "height": 240,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ckQKjcedmZzaBI0GknSo9w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/902cc921431246d14ccd3804173e2b35.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nimbus-therapeutics-announces-research-collaboration-130000326.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nimbus-therapeutics-announces-research-collaboration-130000326.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T12:30:27+00:00",
    "headline": "Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss",
    "summary": "Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.",
    "url": "https://www.investors.com/news/technology/arrowhead-pharmaceuticals-weight-loss-fat-loss-gene-silencing/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "772f1cfe-2b2b-33ba-97c1-abe0e16f3cc2",
      "content": {
        "id": "772f1cfe-2b2b-33ba-97c1-abe0e16f3cc2",
        "contentType": "STORY",
        "title": "Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss",
        "description": "",
        "summary": "Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.",
        "pubDate": "2026-01-06T12:30:27Z",
        "displayTime": "2026-01-06T12:30:27Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/772f1cfe-2b2b-33ba-97c1-abe0e16f3cc2/arrowhead-says-its-gene.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/10c1a05f1de308bdfa56991ef393218d",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GTTamNDY.xTkLNhdAFEHFQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/10c1a05f1de308bdfa56991ef393218d.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wFLjwWqj4ZKHjwdb.mDUAA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/10c1a05f1de308bdfa56991ef393218d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/arrowhead-pharmaceuticals-weight-loss-fat-loss-gene-silencing/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ARWR"
            },
            {
              "symbol": "WVE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T14:30:00+00:00",
    "headline": "Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value?",
    "summary": "Eli Lilly offers investors safety and growth.",
    "url": "https://www.fool.com/investing/2026/01/06/should-you-buy-eli-lilly-before-it-reaches-1-trill/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "46915a36-1c15-36cf-841b-b08a127b0943",
      "content": {
        "id": "46915a36-1c15-36cf-841b-b08a127b0943",
        "contentType": "STORY",
        "title": "Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value?",
        "description": "",
        "summary": "Eli Lilly offers investors safety and growth.",
        "pubDate": "2026-01-06T14:30:00Z",
        "displayTime": "2026-01-06T14:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/8278e3d76f85abf63e07dfd37fd7cf93",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "An investor looks pensively at a computer screen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9Uu.5Pmo1Yt2F_YtLx8bLA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/8278e3d76f85abf63e07dfd37fd7cf93.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PQwoyClB7Msi_tqrtWgcbw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/8278e3d76f85abf63e07dfd37fd7cf93.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/06/should-you-buy-eli-lilly-before-it-reaches-1-trill/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-eli-lilly-reaches-1-143000125.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T16:19:12+00:00",
    "headline": "Google Stock, Lilly And An Aviation Name Are Fund Managers' Favorites",
    "summary": "IBD SwingTrader name Alphabet and IBD 50 watchlist stock Eli Lilly have made the IBD Screen Of The Day, which is focused on Stocks That Funds Are Buying. Google stock is nearing the buy point of a flat base, while Lilly shares pulled back Monday on competitor Novo Nordisk's breakthrough drug launch.",
    "url": "https://www.investors.com/research/google-stock-googl-eli-lilly-lly-alphabet-air-aerospace/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "a1ec8179-4c63-33b3-8819-da7d1f6bd4a2",
      "content": {
        "id": "a1ec8179-4c63-33b3-8819-da7d1f6bd4a2",
        "contentType": "STORY",
        "title": "Google Stock, Lilly And An Aviation Name Are Fund Managers' Favorites",
        "description": "",
        "summary": "IBD SwingTrader name Alphabet and IBD 50 watchlist stock Eli Lilly have made the IBD Screen Of The Day, which is focused on Stocks That Funds Are Buying. Google stock is nearing the buy point of a flat base, while Lilly shares pulled back Monday on competitor Novo Nordisk's breakthrough drug launch.",
        "pubDate": "2026-01-06T16:19:12Z",
        "displayTime": "2026-01-06T16:19:12Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/a1ec8179-4c63-33b3-8819-da7d1f6bd4a2/google-stock-lilly-and-an.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/928d271a2c1510fbc21cc24be3a783e0",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4MBs4SfVL3ohqhlOhEfTQQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/928d271a2c1510fbc21cc24be3a783e0.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XXtf8LiqMXIKH9v1K4h07A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/928d271a2c1510fbc21cc24be3a783e0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/research/google-stock-googl-eli-lilly-lly-alphabet-air-aerospace/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "AIR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T14:41:00+00:00",
    "headline": "Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?",
    "summary": "Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.",
    "url": "https://finance.yahoo.com/news/us-launch-nvos-wegovy-pill-144100630.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "4d273004-6e19-3b48-bcb2-4108dc625d40",
      "content": {
        "id": "4d273004-6e19-3b48-bcb2-4108dc625d40",
        "contentType": "STORY",
        "title": "Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?",
        "description": "",
        "summary": "Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.",
        "pubDate": "2026-01-06T14:41:00Z",
        "displayTime": "2026-01-06T14:41:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JLDGQt80ARh3qkafoo9TaA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ncdWYZW_rP_HUKWXjdodfA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/us-launch-nvos-wegovy-pill-144100630.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/us-launch-nvos-wegovy-pill-144100630.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T16:26:00+00:00",
    "headline": "Zepbound Boost Gets a Lift From Arrowhead’s Drug. The Question Is Whether Patients Will Pay.",
    "summary": "Arrowhead’s experimental therapy helped patients on Lilly’s Zepbound lose more weight and visceral fat—but cost and convenience could limit demand.",
    "url": "https://www.barrons.com/articles/arrowhead-drug-zepbound-weight-loss-trial-a3123991?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "b9f26f02-5efe-3cc6-90cb-a5f655d3723e",
      "content": {
        "id": "b9f26f02-5efe-3cc6-90cb-a5f655d3723e",
        "contentType": "STORY",
        "title": "Zepbound Boost Gets a Lift From Arrowhead’s Drug. The Question Is Whether Patients Will Pay.",
        "description": "",
        "summary": "Arrowhead’s experimental therapy helped patients on Lilly’s Zepbound lose more weight and visceral fat—but cost and convenience could limit demand.",
        "pubDate": "2026-01-06T16:26:00Z",
        "displayTime": "2026-01-06T16:26:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/b9f26f02-5efe-3cc6-90cb-a5f655d3723e/zepbound-boost-gets-a-lift.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/dabeaa48793d46fbea64a7ec1a27af3b",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y4dWySeCJTh3vve8uIp4_g--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/dabeaa48793d46fbea64a7ec1a27af3b.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bQw04QdTOobuMqy6k6ueNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/dabeaa48793d46fbea64a7ec1a27af3b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/arrowhead-drug-zepbound-weight-loss-trial-a3123991?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ARWR"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "WVE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T17:00:02+00:00",
    "headline": "Are You Looking for a Top Momentum Pick? Why Eli Lilly (LLY) is a Great Choice",
    "summary": "Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.",
    "url": "https://finance.yahoo.com/news/looking-top-momentum-pick-why-170002446.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1d32f208-8f6b-30b9-b98d-9a08e5ca6ab4",
      "content": {
        "id": "1d32f208-8f6b-30b9-b98d-9a08e5ca6ab4",
        "contentType": "STORY",
        "title": "Are You Looking for a Top Momentum Pick? Why Eli Lilly (LLY) is a Great Choice",
        "description": "",
        "summary": "Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.",
        "pubDate": "2026-01-06T17:00:02Z",
        "displayTime": "2026-01-06T17:00:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee",
          "originalWidth": 900,
          "originalHeight": 876,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/H7_MbG.UY.XzK7FHlqhSdQ--~B/aD04NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee.cf.webp",
              "width": 900,
              "height": 876,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9cdhr7KlQi2r1salrGcJQg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/looking-top-momentum-pick-why-170002446.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/looking-top-momentum-pick-why-170002446.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T18:28:00+00:00",
    "headline": "Eli Lilly, AI Drug-Discovery Company Nimbus Partner on Oral Obesity Treatment",
    "summary": "Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases.",
    "url": "https://www.wsj.com/health/pharma/eli-lilly-nimbus-partner-to-develop-license-oral-obesity-treatment-65445207?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "fb75da7f-f63a-307f-833b-208d2b6b6941",
      "content": {
        "id": "fb75da7f-f63a-307f-833b-208d2b6b6941",
        "contentType": "STORY",
        "title": "Eli Lilly, AI Drug-Discovery Company Nimbus Partner on Oral Obesity Treatment",
        "description": "",
        "summary": "Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases.",
        "pubDate": "2026-01-06T18:28:00Z",
        "displayTime": "2026-01-06T18:28:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/fb75da7f-f63a-307f-833b-208d2b6b6941/eli-lilly-ai-drug-discovery.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/a084f494945053c772d22b828b565546",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Gjf42WbKNlDheCOwrTBAFg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/a084f494945053c772d22b828b565546.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IAun3HzM6qoeWGkb.qc4jw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/a084f494945053c772d22b828b565546.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/eli-lilly-nimbus-partner-to-develop-license-oral-obesity-treatment-65445207?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T20:59:39+00:00",
    "headline": "Sector Update: Health Care Stocks Gain Late Afternoon",
    "summary": "Health care stocks rose late Tuesday afternoon with the NYSE Health Care Index gaining 1.9% and the",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-gain-205939982.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "b8231ebb-9edf-31f8-88e7-74bf6b06a12f",
      "content": {
        "id": "b8231ebb-9edf-31f8-88e7-74bf6b06a12f",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Gain Late Afternoon",
        "description": "",
        "summary": "Health care stocks rose late Tuesday afternoon with the NYSE Health Care Index gaining 1.9% and the",
        "pubDate": "2026-01-06T20:59:39Z",
        "displayTime": "2026-01-06T20:59:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-gain-205939982.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-gain-205939982.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "UNH"
            },
            {
              "symbol": "BKD"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "TPG"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T20:40:00+00:00",
    "headline": "Eli Lilly Nears Deal for Biotech Ventyx",
    "summary": "Eli Lilly  is in advanced talks to acquire  Ventyx Biosciences  for more than $1 billion, according to people familiar with the matter.  A deal for Ventyx, which specializes in developing pills that can treat inflammatory diseases, could be announced imminently, the people said.  Ventyx, of San Diego, had a market value of a little over $500 million as of Tuesday afternoon.",
    "url": "https://www.wsj.com/health/pharma/eli-lilly-nears-deal-for-biotech-ventyx-3bc666d2?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "51df9a4d-3de9-3571-be26-6d5f895b92c4",
      "content": {
        "id": "51df9a4d-3de9-3571-be26-6d5f895b92c4",
        "contentType": "STORY",
        "title": "Eli Lilly Nears Deal for Biotech Ventyx",
        "description": "",
        "summary": "Eli Lilly  is in advanced talks to acquire  Ventyx Biosciences  for more than $1 billion, according to people familiar with the matter.  A deal for Ventyx, which specializes in developing pills that can treat inflammatory diseases, could be announced imminently, the people said.  Ventyx, of San Diego, had a market value of a little over $500 million as of Tuesday afternoon.",
        "pubDate": "2026-01-06T20:40:00Z",
        "displayTime": "2026-01-06T20:40:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/51df9a4d-3de9-3571-be26-6d5f895b92c4/eli-lilly-nears-deal-for.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7639a479b4889ccdcfd06dfdc20c2470",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3ENIEx0pWOH.W4O48ezfAg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7639a479b4889ccdcfd06dfdc20c2470.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/voNRAHQNLLEeD1JApd7V1Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7639a479b4889ccdcfd06dfdc20c2470.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/eli-lilly-nears-deal-for-biotech-ventyx-3bc666d2?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]